Trial Profile

A phase 1/2 study of OQL051 to evaluate the safety in healthy volunteers, as well as safety and preliminary efficacy of the drug in cancer patients who plan to receive fluorouracil (5-FU) and irinotecan-based chemotherapy

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 09 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jun 2023 New trial record
06 Jun 2023 According to an OnQuality Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its drug candidate, OQL051, for the prophylaxis of chemotherapy-induced diarrhea (CID).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com